Globe Life (NYSE:GL) Announces Earnings Results

Globe Life (NYSE:GL) issued its quarterly earnings results on Wednesday. The company reported $4.84 earnings per share for the quarter, missing analysts’ consensus estimates of $4.90 by ($0.06), Zacks reports. Globe Life had a return on equity of 19.95% and a net margin of 18.89%. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the previous year, the business posted $4.81 earnings per share. The business’s revenue was up 5.5% on a year-over-year basis.

Globe Life Price Performance

GL stock opened at $163.41 on Friday. The stock has a market capitalization of $12.56 billion, a PE ratio of 10.91 and a beta of 0.44. The company’s 50-day moving average is $170.48 and its 200-day moving average is $167.25. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.07 and a quick ratio of 0.07. Globe Life has a 1 year low of $127.85 and a 1 year high of $191.55.

Globe Life Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Monday, October 5th will be issued a dividend of $0.33 per share. The ex-dividend date is Monday, October 5th. This represents a $1.32 annualized dividend and a dividend yield of 0.8%. Globe Life’s dividend payout ratio is currently 8.76%.

Insider Transactions at Globe Life

In related news, CFO Thomas Kalmbach sold 21,000 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $180.06, for a total transaction of $3,781,260.00. Following the transaction, the chief financial officer directly owned 50,568 shares of the company’s stock, valued at approximately $9,105,274.08. This represents a 29.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James Darden sold 50,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $182.43, for a total value of $9,121,500.00. Following the completion of the transaction, the chief executive officer owned 58,451 shares in the company, valued at approximately $10,663,215.93. The trade was a 46.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 143,650 shares of company stock valued at $25,793,717. 2.11% of the stock is currently owned by corporate insiders.

Key Globe Life News

Here are the key news stories impacting Globe Life this week:

• Positive Sentiment: Globe Life reported third-quarter revenue of approximately $1.60 billion, above the $1.56 billion analyst consensus, with revenue up 5.5% year over year. Operating EPS increased to $4.84 from $4.81 a year earlier. Globe Life third-quarter 2026 results
• Positive Sentiment: Management is targeting $850 million to $950 million in parent excess cash flow for 2027, which could support capital returns, debt reduction or other shareholder-friendly actions. The company projects 2027 EPS of $16.10 to $17.10, a range that includes the $16.51 consensus estimate. Globe Life 2027 outlook
• Neutral Sentiment: The company’s 2027 EPS guidance of $16.10 to $17.10 implies continued earnings growth, but the broad range suggests uncertainty around operating performance and future underwriting results.
• Negative Sentiment: Third-quarter operating EPS of $4.84 missed estimates ranging from $4.87 to $4.90. Weaker underwriting income and higher expenses offset gains from increased premiums and investment income. Globe Life Q3 earnings miss
• Negative Sentiment: Globe Life cut its FY 2026 EPS outlook to $15.35-$15.65, below the $15.72 consensus estimate. Reports also cited losses at Evry Health as a factor pressuring the full-year guidance. Evry Health losses and Globe Life guidance
• Negative Sentiment: The quarter included a reported underwriting loss of about $6.4 million, raising investor concerns about claims trends, expense control and the company’s ability to convert premium growth into profits. Globe Life underwriting loss analysis

Wall Street Analyst Weigh In

GL has been the topic of several research analyst reports. UBS Group set a $165.00 target price on Globe Life in a research report on Friday. Jefferies Financial Group lifted their target price on Globe Life from $147.00 to $166.00 and gave the stock a “hold” rating in a report on Friday, July 10th. Weiss Ratings raised Globe Life from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. Piper Sandler lowered Globe Life from an “overweight” rating to a “neutral” rating and set a $165.00 price target on the stock. in a research note on Friday. Finally, Morgan Stanley cut their price target on Globe Life from $208.00 to $197.00 and set an “overweight” rating on the stock in a report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $182.60.

Globe Life declared that its board has initiated a share buyback program on Monday, August 10th that authorizes the company to buy back $2.50 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 17.7% of its stock through open market purchases. Share buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Globe Life Company Profile

Globe Life Inc (NYSE: GL) is an insurance holding company that provides individual life and supplemental health insurance products through a network of wholly owned subsidiaries. Its offerings are designed primarily for middle-income households and include term and whole life insurance, mortgage protection coverage, accident and supplemental health insurance, Medicare supplement policies, and annuities.

The company markets its products through several distribution channels, including exclusive and independent agency networks, direct-to-consumer sales, and workplace or union-affiliated programs.